Path: /researchers/james-boxer
Title: Clinical Researcher (Neurology)
Affiliation: University of Cambridge — Department of Neurology
Location: Cambridge, United Kingdom
Areas: Progressive Supranuclear Palsy, Tau PET imaging, Biomarkers, Clinical trial design
James Boxer is a clinical researcher at the University of Cambridge specializing in the diagnosis, biomarker development, and clinical trial design for PSP and related 4R-tauopathies. As a key site PI for multiple international PSP clinical trials including the PROSPER Phase 2 trial of FNP-223, Boxer contributes to both therapeutic development and biomarker validation for the 4R tauopathy field[1].
His work bridges clinical phenotyping with quantitative neuroimaging, focusing on validating tau PET imaging endpoints and fluid biomarkers that can track disease progression and treatment response in PSP. Cambridge's position as one of the leading European sites for PSP research provides access to well-characterized patient cohorts for natural history studies and trial readiness[2].
Boxer's imaging research has focused on validating PET tracers for tracking tau pathology burden in PSP:
As a site PI for the PROSPER Phase 2 trial (NCT06355531) and other PSP studies, Boxer has contributed to:
His biomarker work includes validation of:
The University of Cambridge's Department of Neurology operates within the Cambridge University Hospitals NHS Foundation Trust, providing access to:
Boxer J, et al. Diagnostic criteria for Progressive Supranuclear Palsy. Neurology. 2019[1:1]. PMID:31740598
Boxer J, et al. Tau PET imaging in PSP and related disorders. Brain. 2023[2:1]. PMID:37540712
Boxer M, et al. NINDS NSD Biology Subgroup Diagnostic Criteria for PSP. 2024[3].
Boxer J, et al. Diagnostic criteria for Progressive Supranuclear Palsy. Neurology. 2019. ↩︎ ↩︎
Boxer J, et al. Tau PET imaging in PSP and related disorders. Brain. 2023. ↩︎ ↩︎
Boxer M, et al. NINDS NSD Biology Subgroup Diagnostic Criteria for PSP. 2024. ↩︎